Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease

High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer

(2014) E. A. Reijm et al.   ANNALS OF ONCOLOGY

Absolute Assignment of Breast Cancer Intrinsic Molecular Subtype

(2014) Eric R. Paquet et al.   JNCI-Journal of the National Cancer Institute

Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic Profiling in Breast Cancer

(2013) M. P. H. M. Jansen et al.   CANCER RESEARCH

Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism

(2013) Jan Budczies et al.   Journal of Proteomics

A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response

(2011) Oscar Krijgsman et al.   BREAST CANCER RESEARCH AND TREATMENT

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

(2011) Matthew J. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes

(2011) Ismahane Bekhouche et al.   PLoS One

Incidence of and survival following brain metastases among women with inflammatory breast cancer

(2010) S. Dawood et al.   ANNALS OF ONCOLOGY

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

(2010) S. Dawood et al.   ANNALS OF ONCOLOGY

Is there a role for mammary stem cells in inflammatory breast carcinoma?

(2010) Steven Van Laere et al.   CANCER

Estrogen-Dependent and Estrogen-Independent Mechanisms Contribute to AIB1-Mediated Tumor Formation

(2010) M. I. Torres-Arzayus et al.   CANCER RESEARCH

Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer with Acquired Endocrine Resistance

(2010) A. F. Leary et al.   CLINICAL CANCER RESEARCH

Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study

(2010) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination

(2010) Ilse Van der Auwera et al.   PLoS One

NF-kappa B genes have a major role in Inflammatory Breast Cancer

(2008) Florence Lerebours et al.   BMC CANCER

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

(2008) Sherene Loi et al.   BMC GENOMICS

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen

(2008) Marleen Kok et al.   BREAST CANCER RESEARCH AND TREATMENT

The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer

(2008) M. Schmidt et al.   CANCER RESEARCH

Relapse-Free Survival in Breast Cancer Patients Is Associated with a Gene Expression Signature Characteristic for Inflammatory Breast Cancer

(2008) S. Van Laere et al.   CLINICAL CANCER RESEARCH

Relevance of Breast Cancer Antiestrogen Resistance Genes in Human Breast Cancer Progression and Tamoxifen Resistance

(2008) Ton van Agthoven et al.   JOURNAL OF CLINICAL ONCOLOGY

Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro

(2008) Sanda Raulic et al.   JOURNAL OF ENDOCRINOLOGY